Medicare expands wound-care coverage while flagging high-billing providers for scrutiny.

What it does

This bill creates a new Medicare payment category for skin substitute products (cellular or tissue-based wound treatments) starting January 1, 2026, sets their payment rate based on a volume-weighted average of 2023 prices adjusted annually for inflation, and establishes fraud-prevention measures including identification of high-billing providers, prepayment review, and prior authorization for outliers. Patients and wound-care providers gain clearer Medicare coverage; the government gains tools to monitor unusual billing patterns.

Why we flagged it

The bill's core mechanism is establishing a new Medicare payment category and rate-setting methodology for a specific product class, paired with program-integrity oversight. It is regulatory/administrative reform, not a subsidy or carve-out.

What the text implies

• Payment rate is locked to October 2023 ASP pricing file, meaning manufacturers cannot influence the baseline through future price changes—this may reduce incentive for innovation or market entry after 2026.
• Volume-weighted average methodology favors high-volume products; lower-volume specialized skin substitutes may receive below-market reimbursement, potentially limiting access to niche treatments.
• Prior authorization and prepayment review apply only to top 3% billing providers, creating a two-tier system where most providers face no scrutiny while outliers face intensive review—may incentivize providers to stay below detection thresholds.
• Section 1834(aa)(5) prohibits coverage denials based solely on clinical evidence analysis in 2026, effectively creating a one-year moratorium on evidence-based coverage restrictions—may allow products with weak clinical support to be reimbursed.
• $5M annual funding for prior authorization (2027–2030) is modest relative to potential skin substitute market size; underfunding could limit effectiveness of fraud detection.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Medicare beneficiaries gain explicit coverage for skin substitute products (previously unclear), with payment rates anchored to historical data rather than manufacturer pricing. Fraud-prevention measures protect the program's integrity without restricting patient access—prior authorization applies only to outlier providers, not all patients.

Who stands to gain

• skin substitute product manufacturers
• wound-care providers and hospitals
• Medicare beneficiaries (expanded access)

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services (HHS), Inspector General of HHS, Federal Supplementary Medical Insurance Trust Fund, Medicare Administrative Contractors, Skin substitute product manufacturers (unnamed)

Where it stands

7 cosponsors: 5 Republicans, 2 Democrats.

• Oct 17, 2025 — Introduced · Congress.gov: “Introduced in House”
• Oct 17, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

13 lobbying clients named this bill on 19 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,510,618 in lobbying spend. A filing names 3 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 94% of bills with at least one filing.

Buddy Carter, the sponsor, reported $988,325 in PAC receipts in the 2026 cycle.

• Smith & Nephew, Inc. — $490,000 on 1 filing
• National Association of Accountable Care Organizations — $276,869 on 2 filings
• Convatec, Inc. F/k/a Triad Life Sciences, Inc. — $170,000 on 2 filings
• Organogenesis Inc. — $150,000 on 2 filings
• Dynamic Medical Services D/b/a Acesso Biologics — $100,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.